Pregabalin for Altered Visceral Pain Processing in Cancer with Liver Metastases

Evidence Supporting Pregabalin as First-Line

The American College of Chest Physicians recommends pregabalin as a first-line adjuvant analgesic for neuropathic cancer pain, particularly when combined with opioids, due to its superior efficacy and more favorable safety profile in the setting of hepatic dysfunction 1, 2, 3
Pregabalin demonstrated significantly greater pain reduction compared to amitriptyline, gabapentin, and placebo in a direct comparison trial of 120 patients with severe cancer-related neuropathic pain, representing the highest quality evidence directly addressing this question 1
The National Comprehensive Cancer Network (NCCN) consistently recommends pregabalin as a first-line adjuvant analgesic for neuropathic cancer pain, particularly when combined with opioids 2, 3

Amitriptyline carries significant hepatotoxicity risk and is extensively metabolized by the liver, making it problematic in patients with hepatic metastases, according to the Korean practice guidelines 4
Pregabalin is renally cleared and does not undergo hepatic metabolism, making it inherently safer in the setting of liver dysfunction, although dose adjustment is required if renal impairment develops 2

The initial pregabalin dosing should start at 50 mg three times daily (or 25 mg three times daily in elderly/frail patients), with a maximum dose of 600 mg daily in divided doses, and dose reduction required if creatinine clearance <60 mL/min 2, 5

The NCCN recommends combining adjuvant medications with opioids for synergistic effects in treatment-resistant neuropathic pain, and considering adding topical lidocaine 5% patch for localized pain components 2, 3, 5

Pregabalin requires oral administration, and if the patient develops oral feeding difficulties, there is no alternative route, although this information is not directly cited [5 is related but does not directly address this point, hence not included]
Consider adding topical lidocaine 5% patch for localized pain components, as it has minimal systemic absorption and is safe in hepatic dysfunction, as recommended by the NCCN and other guidelines 2, 3, 5
Titrate slowly in elderly or medically frail patients, as both medications can cause sedation and cognitive impairment, according to the NCCN guidelines 2